Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2021; 27(31): 5171-5180
Published online Aug 21, 2021. doi: 10.3748/wjg.v27.i31.5171
Published online Aug 21, 2021. doi: 10.3748/wjg.v27.i31.5171
Molecular advances in pancreatic cancer: A genomic, proteomic and metabolomic approach
Srujan Rajesh, Michael J Cox, Franscois Runau, Department of General Surgery, Leicester General Hospital, Leicester LE5 4PW, United Kingdom
Author contributions: Rajesh S, Cox MJ and Runau F contributed equally in the conception, preparation and finalization of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interest in this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Franscois Runau, FRCS (Gen Surg), PhD, Academic Fellow, Surgeon, Department of General Surgery, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, United Kingdom. franscois_gerald@yahoo.com
Received: January 25, 2021
Peer-review started: January 25, 2021
First decision: March 29, 2021
Revised: April 11, 2021
Accepted: August 3, 2021
Article in press: August 3, 2021
Published online: August 21, 2021
Processing time: 204 Days and 9.6 Hours
Peer-review started: January 25, 2021
First decision: March 29, 2021
Revised: April 11, 2021
Accepted: August 3, 2021
Article in press: August 3, 2021
Published online: August 21, 2021
Processing time: 204 Days and 9.6 Hours
Core Tip
Core Tip: Treatment for pancreatic ductal adenocarcinoma is limited by the severity of the pathology, limited biomarkers and late presentation of patients. Utilising genomic, proteomic and metabolomic research into pancreatic ductal adenocarcinoma has provided insight into understanding the disease process as well as providing suitable markers of diagnosis and treatment to improve clinical outcomes.